April 2015 in “Plastic and Reconstructive Surgery” Activating TLR3 helps improve skin and hair follicle regeneration after wounds.
April 2020 in “The Aesthetics” LED-LLLT helps heal wounds, reduce pain, and regrow hair using specific light wavelengths.
11 citations
,
April 2012 in “Journal of Investigative Dermatology” A specific mutation in PA-PLA1α causes abnormal hair growth.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
Plakophilin 1 helps control skin cell immune responses to prevent excessive inflammation.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
10 citations
,
January 2020 in “Journal of Materials Chemistry B” The biofilm enhances skin healing by promoting cell growth and blood vessel formation.
14 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Platelet-rich plasma might be a new way to treat lichen planopilaris.
32 citations
,
August 1982 in “Journal of the American Academy of Dermatology” GLPLS and LPP are variants of lichen planus.
64 citations
,
October 2020 in “Journal of lasers in medical sciences” Low-level laser therapy shows promise but needs more research for improvement.
30 citations
,
February 2010 in “The journal of investigative dermatology/Journal of investigative dermatology” Plet-1 protein helps hair follicle cells move and stick to tissues.
12 citations
,
May 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin 332 is essential for normal skin cell behavior and structure.
July 2003 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not available for parsing.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” The STRIPAK complex is crucial for skin cell organization and creating a functional skin barrier.
February 2025 in “Journal of Clinical Investigation” RNase L hinders hair growth by altering immune signals.
September 2024 in “Journal of Ethnopharmacology” Terminalia bellirica extracts effectively promote hair regrowth and treat androgenetic alopecia.
VB-1, a natural compound, may promote hair growth by enhancing important cell signaling and increasing key gene expression.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
17 citations
,
November 2017 in “PLoS ONE” Transplanted bone marrow cells actively move, form clusters, and grow after transplantation.
2 citations
,
May 2023 in “Life” Plumbagin may help protect cells, reduce inflammation, and has potential for treating various diseases, but more research is needed.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
January 2000 in “Cambio 16” Bcl-2 affects hair growth and pigmentation by controlling cell death.
Lhx2 is a crucial regulator of the Sonic Hedgehog signaling in early mouse retinal development.
January 2026 in “RSC Advances” 1 citations
,
May 2022 in “International journal of molecular sciences” Faulty LEF1 activation causes faster skin cell differentiation in premature aging syndrome.
48 citations
,
November 2018 in “Journal of dermatological treatment” Women are more likely to have Lichen planopilaris, and treatments with cyclosporine and methotrexate are most effective but less safe than mycophenolate mofetil.
February 2023 in “Journal of dermatology” The first Japanese case of a genetic hair disorder caused by specific mutations in the LIPH gene was identified.
February 2024 in “Health Sciences” Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.
14 citations
,
August 2014 in “The FASEB Journal” CAP1/Prss8 does not activate PAR2 or inhibit PN-1.